DURHAM, N.C., April 4, 2022 /PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback